Please login to the form below

Not currently logged in

NICE backs Pfizer drug in kidney cancer

Inlyta near end of two-year struggle for recommendation
Pfizer Inlyta axitinib

Pfizer's Inlyta is finally on course for routine use on the NHS in England and Wales after being recommended in final draft guidance.

The National Institute for Health and Care Excellence (NICE), which provides healthcare guidance for the NHS, backed the use of Inlyta (axitinib) in advanced kidney cancer two years after turning down the drug in the indication in draft guidance.

At the time NICE's chief executive criticised the data provided by Pfizer as it lacked a comparison to 'best supportive care' among other concerns.

Pfizer appealed the decision with the submission of extra data and the introduction of a discount through a patient access scheme leading to a change of heart from NICE earlier this year when it posted subsequent draft guidance in March.

Now the organisation has issued final draft guidance that recommends Inlyta as a treatment for advanced renal cell carcinoma in patients who have failed treatment with a first line tyrosine kinase inhibitor or a cytokine.

Prof Carole Longson, director of NICE's Health Technology Evaluation Centre said: “NICE was asked by the Department of Health to look at axitinib for people who have already been treated with a cytokine or a drug known as a kinase inhibitor. This draft guidance recommends that the NHS provides axitinib for these patients.

“Although, this recommendation has not changed since the previous draft guidance, the updated draft includes some clarification around prescribing axitinib.

The draft guidance is now up for further consultation with final guidance to published soon. Until then the drug is available via the Cancer Drugs Fund.

Article by
Thomas Meek

16th December 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...